Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label Study of ABSK112 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Non-Small Cell Lung Cancer

NCT06225804 is registered in ClinicalTrials.gov with Abbisko Therapeutics Co, Ltd as lead sponsor.

NCT NCT06225804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06225804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label Study of ABSK112 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Non-Small Cell Lung Cancer
Lead sponsor
Abbisko Therapeutics Co, Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
February 22, 2024
Completion date
March 31, 2028
Enrollment
164 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer